Resveratrol against Cardiac Fibrosis: Research Progress in Experimental Animal Models

Molecules. 2021 Nov 13;26(22):6860. doi: 10.3390/molecules26226860.

Abstract

Cardiac fibrosis is a heterogeneous disease, which is characterized by abundant proliferation of interstitial collagen, disordered arrangement, collagen network reconstruction, increased cardiac stiffness, and decreased systolic and diastolic functions, consequently developing into cardiac insufficiency. With several factors participating in and regulating the occurrence and development of cardiac fibrosis, a complex molecular mechanism underlies the disease. Moreover, cardiac fibrosis is closely related to hypertension, myocardial infarction, viral myocarditis, atherosclerosis, and diabetes, which can lead to serious complications such as heart failure, arrhythmia, and sudden cardiac death, thus seriously threatening human life and health. Resveratrol, with the chemical name 3,5,4'-trihydroxy-trans-stilbene, is a polyphenol abundantly present in grapes and red wine. It is known to prevent the occurrence and development of cardiovascular diseases. In addition, it may resist cardiac fibrosis through a variety of growth factors, cytokines, and several cell signaling pathways, thus exerting a protective effect on the heart.

Keywords: cardiac fibrosis; cardiac fibrosis-related diseases; resveratrol.

Publication types

  • Review

MeSH terms

  • Animals
  • Antifibrotic Agents / pharmacology
  • Antifibrotic Agents / therapeutic use*
  • Antioxidants / pharmacology
  • Antioxidants / therapeutic use*
  • Disease Models, Animal
  • Heart / drug effects
  • Heart Diseases / drug therapy*
  • Heart Diseases / pathology
  • Humans
  • Myocardium / pathology*
  • Resveratrol / pharmacology
  • Resveratrol / therapeutic use*

Substances

  • Antifibrotic Agents
  • Antioxidants
  • Resveratrol